Efficacy of antiviral agents in moderate to severe COVID-19 in pediatrics – a pilot RCT

Dept of Pediatrics Medical College Kolkata0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1) High initial clinical suspicion by physician as SARI based on signs and symptoms (fever, cough, myalgias, fatigue, shortness of breath) followed by positive RT-PCR/ True NAAT/ Antigen test in Nasopharyngeal/ oropharyngeal swab for confirmation of COVID-19 diagnosis
•Referred from other center as COVID-19 + by RT-PCR/ True NAAT/ Antigen in NPS/OPS
•2) Moderate to severe COVID-19 symptoms
•3) Willing to give informed written consent

•i.Unable to take enteral drug (orally or by NG tube)
•ii.Known hypersensitivity to HCQs or other 4-aminoquinoline compounds, or doxycycline
•iii.Already taking HCQs or chloroquine within 1 month due to any reason
•iv.Known G6-PD deficiency
•v.History of retinopathy
•vi.History of congenital cardiac diseases
•vii.QTc > 440 mS at admission, abnormal cardiac rhythm at screening
•viii.Suspected or proven scrub typhus
•ix.Suspected or proven malaria
•x.Patient terminally moribund and unlikely to survive beyond 24 hrs as per physician’s discretion
•xi.Participation in any other clinical trial of an experimental agent treatment for COVID-19
•xii.Concurrent treatment with other agents with direct acting antiviral activity against COVID-19
•xiii.Requiring mechanical ventilation at screening

发起方

Dept of Pediatrics Medical College Kolkata